NCT06637501 2026-04-16
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2 Active not recruiting
Clinical Trials
661 trialsNCT07221500 2026-04-14
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
Phase 2 Recruiting
NCT07529405 2026-04-14
CurbMF
Virogen Biotechnology Inc.
Phase 2 Not yet recruiting
NCT04728893 2026-04-13
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05283720 2026-04-13
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT05963074 2026-04-13
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07387471 2026-04-13
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
Phase 2 Recruiting
NCT06745583 2026-04-09
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase 2 Recruiting
NCT05660967 2026-04-08
EPCORE DLBCL-3
Genmab
Phase 2 Active not recruiting
NCT07029737 2026-04-08
SOUND-MCL
AstraZeneca
Phase 2 Recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT06890884 2026-04-02
MK-2140-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05020015 2026-03-31
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Takeda
Phase 2 Active not recruiting
NCT06806033 2026-03-31
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT06854653 2026-03-31
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
NCT03156790 2026-03-30
PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia
medac GmbH
Phase 2 Terminated
NCT07271667 2026-03-30
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc.
Phase 2 Recruiting
NCT05147467 2026-03-27
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 2 Recruiting
NCT06915246 2026-03-27
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS LLC
Phase 2 Recruiting
NCT02717611 2026-03-25
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Acerta Pharma BV
Phase 2 Active not recruiting
NCT05068440 2026-03-25
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
BeOne Medicines
Phase 2 Completed
NCT06588478 2026-03-24
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 2 Recruiting
NCT07015242 2026-03-24
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT02180724 2026-03-20
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Acerta Pharma BV
Phase 2 Active not recruiting
NCT05748171 2026-03-20
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
Phase 2 Recruiting
NCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
NCT02952508 2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2 Active not recruiting
NCT05962606 2026-03-18
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
Aptarion Biotech AG
Phase 2 Completed
NCT06500273 2026-03-18
ALPHA3
Allogene Therapeutics
Phase 2 Recruiting
NCT07477366 2026-03-17
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT07125872 2026-03-16
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
ImmunityBio, Inc.
Phase 2 Recruiting
NCT03876769 2026-03-13
CASSIOPEIA
Novartis
Phase 2 Active not recruiting
NCT05458297 2026-03-12
MK-2140-006
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT02568267 2026-03-06
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05207670 2026-03-05
MorningSun
Genentech, Inc.
Phase 2 Active not recruiting
NCT05479994 2026-03-04
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
Phase 2 Active not recruiting
NCT06539195 2026-03-04
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
Dizal Pharmaceuticals
Phase 2 Active not recruiting
NCT05023018 2026-03-02
NEO100 and High-Grade Meningioma
Neonc Technologies, Inc.
Phase 2 Recruiting
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT06524375 2026-02-25
BRAVE
Genentech, Inc.
Phase 2 Active not recruiting
NCT06526793 2026-02-25
SOUNDTRACK-B
AstraZeneca
Phase 2 Recruiting
NCT04554914 2026-02-20
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Recruiting
NCT03407144 2026-02-19
MK-3475-667
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03332017 2026-02-18
ROSEWOOD
BeOne Medicines
Phase 2 Completed
NCT04569032 2026-02-18
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Phase 2 Completed
NCT04570423 2026-02-18
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals, Inc
Phase 2 Recruiting
NCT04980222 2026-02-17
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05144841 2026-02-13
MK-2140-004
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting